Good afternoon, and thank you for joining us at the Canaccord Genuity MedTech and Diagnostics Conference. My name is Caitlin Roberts. I am one of the medical device analysts here at Canaccord Genuity, and with us today is SofWave, who has an innovative non-invasive face and body technology platform for improving skin laxity, lift, and tone. With me today is SofWave CFO, Assaf Korner. We will start here with a brief presentation and potentially leave some time for Q&A. Before we begin, I want to remind everyone of any relevant disclosures, which can be found on our conference and firm website. With that, let us turn it over to Assaf.
Thank you very much, Caitlin, and good afternoon, everybody. This presentation is covered by safe harbor regulations, so please everybody take a second to look and read the disclaimer. I am Assaf Korner. I am the CFO for SofWave Medical. SofWave Medical has a patented protected next-generation ultrasound beam technology for safe, completely non-invasive head, neck, and body skin regeneration. We have broad range of 12 FDA clearances for lifting, laxity, wrinkle treatment on the face and on the body, as well as reduction of acne scars. We also have unique and proprietary muscle toning technology that I will cover in the following slides. We have a strong revenue growth profile. We just released our earnings last week. We posted $28.5 million of revenue in the third quarter of this year, representing a 35% year-over-year growth.
In terms of CAGR over the last five years, from 2021 to 2025, we grew by 42% CAGR. We have a superior treatment model and ROI for our clinicians, for the clinics, for our customers, that I will touch upon in the following slides. But we basically make money on selling the capital equipment, but as well as getting a portion of every treatment that is being done by our customers. We are a global company. We sell in approximately 55 different countries across the world. We are publicly traded on the Tel Aviv Stock Exchange, went public in 2021. We announced that we sold approximately 3,400 SofWave systems since inception. This is the ultrasound technology. We have 12 FDA clearances, and we talked about the revenue growth profile. Dive a little bit deeper in our Q3 2026 numbers.
Revenue top line grew by 35%, and out of the $28.5 million of revenue, 47% of this revenue, $13.3 million, did not come from selling the capital equipment, from selling the equipment, but actually came from the utilization of the device. So 47% of our revenue coming from our customers who bought the capital equipment from actually using and treating patients with the devices. We have a very healthy gross margin profile. We have a nice gross margin on the equipment, but we also have a consumable that we like to call a virtual consumable. It is basically a software code.
I will touch upon this a little bit later, but every time that the customers click on our applicator or shoot an ultrasound beam from the applicator, we get paid, and this is a virtual consumable that comes at close to 100% gross margin, which creates a blended healthy gross margin of 76.6% in the last quarter. We are profitable and cash flow positive. We actually posted $4.6 million of non-IFRS net income of $4.1 million IFRS income in the third quarter. Cash position, we have over $41 million in the bank as of the end of the third quarter, and we estimated that we performed 1.1 million treatments with our devices.
If we look a little bit deeper into the Q3 numbers, on the left-hand side, we see the graph of the utilization fee or the usage fee revenue growing quite significantly all the way from $5.4 million only two years ago to $13.3 million in the third quarter of 2026. That represents actually a 60% year-over-year growth in terms of utilization. We do see a little bit of seasonality in the third quarter, which is very common for the aesthetic business, but we see substantial growth year- over- year. So 47% of the revenue coming from utilization, 17.2% non-IFRS operating income growing from 8.9% only a year ago, six consecutive quarters of profitability, and not only the recurring revenue, the utilization fee growing, but we also grew by 19% in selling capital equipment in the third quarter of this year. Few words about the people behind the company.
On the left side, we see Dr. Shimon Eckhouse. He is our Chairman and Co-Founder. Dr. Eckhouse is considered to be one of the founding fathers of the energy-based devices in aesthetic medicine. He is the person behind Lumenis. He is also the Co-Founder of Syneron, that then became Syneron Candela. This is the third large public company that Shimon is co-founding in the space. He's also a very well-known entrepreneur in Israel with many, many exits under his belt. He's the inventor of IPL and has over 100 patents under his name, and he's been in the aesthetic industry for over 30 years. Our CEO, Mr. Louis Scafuri, who's not here today, but he comes with a very extensive background and experience in aesthetics, over 25 years in the space. He was in a leadership position with Lumenis.
He was then the CEO of Syneron Candela, one of the largest companies in the space, and he's been our CEO since 2019. We are very lucky to have somebody with Lou's profile to run a company like us. I've been in public and private life science companies for over 20 years, but over 15 of them are in the aesthetic space. I'm not going to go name by name here, but almost everybody that you see on this slide have many, many years of experience in aesthetic medicine and energy-based devices specifically. The medical aesthetic space is entering what we see as a multi-year structural expansion that has four different forces driving it. First and foremost, we see conversion patient group. We see new patient groups that we didn't have before as part of the aesthetic industry. First and foremost, the GLP-1 patients.
A lot of people, and some data showing that one out of eight adults in the U.S. either were on GLP-1 or are on GLP-1 right now, and this number is probably understated. A lot of people are losing weight safely and quickly, and when you lose weight, you are left with, you lose volume on your face, on your body, on your neck, and you are left with saggy skin that needs to be tightened, and this is exactly what we do with our ultrasound technology. On the other hand, what many people do not know is that when you lose weight, you do not only lose weight from fat, you also lose weight from muscle, and the muscle needs to be strengthened, needs to be toned, and that is what we do with our complementary muscle stimulation device that we will talk about in the next few slides.
We see GLP-1 patients, we see menopause patients, we see the longevity patients. People are talking about living longer, but living also healthier, so the whole trend of longevity. We see consumer brand pull. We see consumer awareness in the space really growing. 10, 15, 20 years ago, patients used to go to the dermatologist and ask, "What is the best treatment for my skin situation?" And used to get the advice of a dermatologist or plastic surgeon. Today, consumers have the power to do the research, and the brand and the demand for the treatment are coming from the patients. The patients are telling the physicians what they want, what they saw online, what they read about, what they asked ChatGPT about, and we will talk a little bit about our digital strategy, but we have a quite robust digital brand awareness strategy.
We see a shift to natural regeneration. People want natural look, natural outcomes, minimal downtime. Our devices are completely non-invasively, and the comfort really, really matters. That is all creating, and we talked about the longevity trend, this is all creating an expansion of the treatment options that driving the market growth from about $63 billion in consumer spending on medical aesthetic treatments to what is projected to be $97 billion, growing at 9% CAGR by 2029. Few words about our technology. Our ultrasound technology is unique, proprietary, and clinically validated ultrasound technology. Seven ultrasounds transducers that work in parallel to the skin and creating a thermal injury in the mid-dermis, 1.5 mm deep under the epidermis, to create a thermal injury exactly where collagen and elastin are being produced in our body.
This is what our body is slowing down in production as we grow older. As we get older, our body produces less collagen and elastin. These are the two main components that make our skin look young, healthy, tight, and so on. Us creating this thermal injury in the mid-dermis, we are creating the body to regenerate this collagen and elastin. Not only it is completely non-invasive, we go through the epidermis into the mid-dermis layer without damaging the epidermis at all, we also have proprietary cooling technology. Here on the picture, you see the head of the applicator with the seven ultrasound transducers. If you put your hand on the applicator, it is actually cold. We have proprietary unique technology that is cooling down the epidermis and protecting it while we are generating the energy, the ultrasound energy, and sending it into the mid-dermis.
We are creating a very safe treatment, very comfortable for the patients. There is no bleeding. It is completely non-invasive, and it is also very easy for the clinicians to delegate it to anybody in their office. You do not need the physician themselves do the treatment. Anybody in their office, either it is a technician or RN or physician assistant, can do it in a safe manner. A few words about our revenue model. We are selling capital equipment. We start with selling a box. This is the ultrasound device here on the left side. The MSRP here in the U.S. is $115,000. The ASP is a little bit under $100,000. They buy the capital equipment that comes pre-loaded with 3,000 pulses, 3,000 clicks on the applicator.
3,000 clicks on the applicators are good enough for about 10 - 15 patients, and after the initial 10 - 15 patients, they need to come back and purchase additional pulses in order to continue to utilize the device. Every treatment requires around 200, maybe 300 pulses, depends on the treated area and where exactly you treat the patients, and we take a price list of $1.50 for every pulse. That means that we generate between $225 - $300 from every treatment performed by our systems out there in the field. We said that we installed, sold 3,400 systems worldwide. We created 3,400 partnerships with physicians that every time that they turn on the machine and make a treatment, we take a small piece of the revenue.
We designed the business model not only to work for us and be profitable for us, like we saw in the previous slide, but we also create a business model that will be very attractive for the physicians. We want the physicians to make money and to be successful with our business model. Most of them can get back their money and their return on investment within less than six months. We have minimum advertised price including in our contract, so we enforce the advertised price of our treatments in the market. We actually know when our customer is using the device because of the virtual consumable component. We know exactly when customers buy pulses and when they use the device, and we see that the average median ROI for a clinic here in the U.S. is at 182% in the first 12 months of ownership.
We create a win-win situation, a business model that works for us very well, but also make a lot of profit for our physicians, for our customers. We talked a little bit about the muscle stimulation. What we are doing here is a part of this strategy of going after the GLP-1 patients. We created the one platform that gives the full solution for clinics who see GLP-1 patients. As we said before, many clinics today see GLP-1 patients. We have the skin tightening with 12 FDA clearances, with a lot of clinical data backed. We have a large number of clinical trials that I will review in the next slides. On the other end, what these patients need besides of skin tightening, they need muscle toning, they need to strengthen the muscles as part of their GLP-1 and weight loss journey.
We are providing this one platform exactly for clinicians and clinics who see GLP-1 patients. Clinical evidence and clinical research is one of our core competencies. We have done over 14 clinical studies. We have 12 FDA clearances. This is very unusual in the aesthetic space. Usually, you go out with new technology, you get one or two clearances from the FDA, and you go out and market it. We really invested in data. Every clinical trial that we did, we did with 60, 70, 80 patients, with a total of more than 600 studied subject to date, with over 1,000 treatments made. That created a large number of FDA clearances that we have all the way from laxity, eyebrow lift, which is quite a unique clearance, all the way to arm lift, cellulite.
We even have acne scars approval, and we get great results on the face and the neck. The before and after picture on the neck is quite impressive. Again, completely non-invasively, and I forgot to say, but even more importantly, with no downtime at all. Many of the current more ablative or invasive technologies require downtime after the treatment, whether it is ablative laser, or it is microneedling RF, creating bleeding, redness, and people need to stay home for a few days, up to a week sometimes, in order to recover from the treatment. This is a lunchtime procedure. You go in, you do the procedure in 30, 45 minutes, you go out exactly the same way you came in. No bleeding and very little side effects, if any.
In terms of brand awareness, I mentioned before how important it is today to educate the consumers and have the demand for the treatment and for the devices to come down from the consumers bottom up, not necessarily from the physician. One of the first thing that we have done is to invest heavily and build internally the infrastructure for digital marketing. We have today what we see as 58% share of voice in our field. We have an increase in mention shares year- over- year, about quarter- over- quarter by three points to 38%. Our engagement share continue to go up. Our brand sentiment is at 94%. All this being measured by a specialist. 94% means that 94% of the people that talk about the brand online say positive things about it, versus only 6% saying negative things about the company and the treatment.
We have over 600,000 monthly website users growing by almost 200% year- over- year, 1.6 million and more followers on social media. That is creating a lot of the demand for our treatments and also for our devices to come and being generated by marketing, lead and marketing activity. A very exciting and important development, really fresh from the end of September 24th, we actually received an NMPA approval in China. NMPA is the Chinese FDA. This is a process that we started back then in 2022. It is a long process to get the regulatory approval in China. As part of this process, our local partner in China, a company called HTDK, performed a large clinical study, probably the largest one that I am aware of in aesthetics, with close to 200 patients across five sites, five different hospitals, and got great results on local patients.
First of all, it's great to have such a large clinical trial, but having it done locally on the local patients, providing the local clinical proof that will help selling this to physicians and to patients in China. Chinese market and the size of the Chinese market, I don't need to tell you too much about it, but it's quite robust. Again, we are building our model in China the same way we built it in any other country in the world, which is sell of the capital equipment and then take a piece of the utilization. A few words about HTDK, they are our partner or distributor in China. They are owned by Warburg Pincus, large American private equity. They are very senior, been in the market in China for over 100 years.
They sell to over 10,000 medical institution, over 53 brands, and they have 3,000 subsidiaries. We are going to be the first aesthetic device that they bring to the market. This is a big initiative for HTDK. They appointed Peter Lyu to be the CEO of this new established division of aesthetic. Peter Lyu comes from Solta and Fotona in China, two very large Western brands, very successful in China. Warburg Pincus and HTDK are very much invested. They invested heavily in the clinical trial, as I mentioned before. Clinical trial was not only long and 200 patients, but was also an expensive trial to fund. In addition to that, they are investing quite heavily in building the infrastructure to prepare the commercialization in China.
We did disclose that as part of this approval, we received an opening order for 70 SofWave systems at the end of September. 10 were delivered in the third quarter, and 60 are going to be delivered in the fourth quarter of 2026. A few updates on our KPIs and initiatives for the rest of the year. We are increasing the field productivity and the number of salespeople here in the U.S. Just a few words about how we sell. We sell directly with our own sales force in the U.S. and in the U.K. Everywhere else, 50+ countries worldwide, we sell through distributors. We are continuing to increase and invest in the infrastructure of our direct operations here in the U.S. We are preparing the company for a China launch. We continue to scale internationally.
51% of our revenue in the third quarter came from OUS, from outside of the U.S. The fastest-growing market outside of the U.S. is Asia Pacific. 37% of our revenue in the third quarter came from Asia, leading by Korea, Japan, Australia, and now we have a new, very exciting market in Asia, which is the Chinese market. Expanding our marketing engine in terms of the share of voice and the brand awareness. We are working on the next generation platform, and we expand to treat the body. We talked about the body in terms of the Pure Impact and the muscle toning technology device, but we also launched last year a large applicator for the ultrasound device.
The large applicator is intended to make the treatments on the body, moving from face and neck to treat the body and to do the skin tightening all over the body, and to do it more efficient because it is a larger applicator, more comfortable, and faster for the clinicians as well as for the patient. We see the pulses not being shot only on the face and the neck, but slowly moving also to the body. A quick review of our revenue growth over the last few years. First of all, on the left-hand side, we see our third quarter revenue growing this quarter to 28.5%, growing 35% year-over-year. It is actually nice to see it is growing tenfold from 2021, only $2.8 million to $28 million. Quite a nice story.
In terms of our annual revenue, we finished last year, 2025, with $87.6 million, growing at a CAGR of 42% since 2021. In terms of our quarterly revenue growth, we see quite a nice growth in each one of these quarters, in each one of the years, but we actually see a nice acceleration in 2025, fueled by our regulatory approvals in Japan, our expansion in Korea, as well as our expansion for additional treatment here in the U.S. It is nice to see that the third quarter of this year was $28.5 million, which in the third quarter, which is considered to be the weakest quarter in terms of seasonality in the aesthetic business, reached almost the revenues in the fourth quarter of last year of $29 million, when the fourth quarter is considered by far to be the strongest quarter in the aesthetic industry.
Talked a little bit about the geographical split, I am not going to go through this again, but 49% North America, 37% in Asia. It is worthwhile saying that we still have a significant room for geographical expansion. We are selling in less than 60 countries right now. We know that there are more opportunities to sell in additional large countries in Latin America, in Europe, as well as in Asia. Operating income, which used to be operating loss, the trend is quite nicely reaching to all-time net income as well as operating income. Operating income hit $4.9 million on a non-IFRS basis in the third quarter of 2026. Looking a little bit at our P&L for the third quarter, we talked a little bit about the gross margin, and we see a nice improvement in the gross margin year-over-year, from 73.7% to 76.7%.
This is a result of the increase in utilization and the portion of the pulses that comes at a very low cost of goods, almost no cost of goods at all, contributing to the overall increase in gross margin. We also see a very nice leverage on our operating expenses in general. R&D, we invest quite heavily in R&D already, and we are planning to continue to invest, but this is not growing as percentage of revenue. This is not growing at the pace of the revenue growth. Same is right for the G&A. We also have nice leverage on our sales and marketing expenses. Sales and marketing expenses as percentage of revenues went down from 70% to 60%, 40%, and now we are at low 40%, and we actually hit 39% of sales and marketing expenses in the third quarter of 2026.
This is all creating quite a nice, robust increase in our operating income as well as the net income. The non-IFRS operating income increased by 161% to over 17%, and the non-IFRS net income in the third quarter increased by 235% to 16% of revenue. When we look at the P&L for the first nine months of the year, we see a quite similar trend. As we saw in the third quarter, gross margin continued to improve. Operating expenses going down as percentage of revenue. Non-IFRS net income and non-IFRS operating income increased quite significantly year- over- year. A quick look at our balance sheet. We have a very healthy balance sheet with $41.4 million as of the end of September. We are cash flow positive. We generated $2.6 million of cash in the third quarter.
We have no debt on the balance sheet, so it is quite a clean balance sheet and a nice cash flow story. I see we have 30 seconds. To just summarizing the presentation and the quarter, grew 35%, positive non-IFRS operating margin of over 17%. Utilization fees are climbing up to 47% of our total revenue, up 60% year- over- year. Over 1 million treatments performed with the SofWave systems worldwide, and we received the China approval, the NMPA approval, with our partner HTDK. I did it with six seconds left. Thank you.